Vcanbio Cell & Gene Engineering (600645) Fundamentals 2026 — P/E 78.2x, Revenue Analysis | SniperIQ
Vcanbio Cell & Gene Engineering (600645) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥8.4B, trading at ¥18.48 on the SHH. This SniperIQ fundamentals page covers Vcanbio Cell & Gene Engineering's valuation (P/E 78.2x, P/B 2.4x), profitability (net margin 7.7%), revenue (¥1.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Vcanbio Cell & Gene Engineering's market cap?
Vcanbio Cell & Gene Engineering (600645) has a market capitalization of approximately ¥8.4B, trading at ¥18.48 on the SHH. Market cap moves with the live share price.
What is Vcanbio Cell & Gene Engineering's P/E ratio?
Vcanbio Cell & Gene Engineering's trailing twelve-month P/E ratio is 78.2x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Vcanbio Cell & Gene Engineering?
Vcanbio Cell & Gene Engineering runs a net profit margin of 7.7%, a gross margin of 69.7%, and an operating margin of 11.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Vcanbio Cell & Gene Engineering generate?
Vcanbio Cell & Gene Engineering reported revenue of ¥1.5B for fiscal year 2025, with net income of ¥114M and earnings per share (EPS) of 0.25. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Vcanbio Cell & Gene Engineering pay a dividend?
Vcanbio Cell & Gene Engineering does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Vcanbio Cell & Gene Engineering financially healthy?
Vcanbio Cell & Gene Engineering carries a debt-to-equity ratio of 0.02x and a current ratio of 1.88x, with a market beta of -0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Vcanbio Cell & Gene Engineering a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Vcanbio Cell & Gene Engineering (600645) the key facts are: market cap ¥8.4B, P/E 78.2x, revenue ¥1.5B, 52-week range 16.24-32.99. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Vcanbio Cell & Gene Engineering's full fundamentals live
Get Vcanbio Cell & Gene Engineering's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.